Project Details
Description
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
| Status | Finished |
|---|---|
| Effective start/end date | 12/20/16 → 12/31/18 |
Funding
- BOEHRINGER-INGELHEIM PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.